3-Hydroxy-pyridine-2-carboxamidine | 1208071-22-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Hydroxy-pyridine-2-carboxamidine
• 英文别名: hydroxy-pyridine-2-carboximidamide；hydroxy-2-pyridinecarboximidamide；hydroxypyridine-2a-carboxamidine；3-hydroxypicolinimidamide；hydroxypicolinimidamide；3-hydroxy-2-Pyridinecarboximidamide；3-hydroxypyridine-2-carboximidamide
• CAS: 1208071-22-0
• 化学式: C₆H₇N₃O
• 分子量: 137.141
• InChiKey: MHBWLFBRFFFVTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-Hydroxy-pyridine-2-carboxamidine 在 sodium tetrahydroborate 、 水 、 sodium ethanolate 、 nickel dichloride 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 生成 2-[2-(3-hydroxypyridin-2-yl)-6-oxo-1H-pyrimidin-5-yl]acetic acid
  参考文献：
  名称：

  Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation

  摘要：

  The design, synthesis, and capacity to inhibit HIF prolyl 4-hydroxylases (PHDs) are described for 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide analogs. These analogs revealed two kinds of novel scaffolds as PHD2 inhibitors. Synthetic routes were developed for the preparation of their analogs containing the new scaffolds. In addition, the structure-activity relationship (SAR) of the 2-[2-(3-hydroxy-pyridin-2yl)-thiazol-4-yl]-acetamide derivatives and their biological activities were reported. The complex structure of compound 18 with PHD2 was also obtained for the purpose of more efficient lead optimization. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.003
• 作为产物：
  描述：

  异噁唑并[4,5-b]吡啶-3-胺 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 生成 3-Hydroxy-pyridine-2-carboxamidine
  参考文献：
  名称：

  Discovery of novel 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide derivatives as HIF prolyl 4-hydroxylase inhibitors; SAR, synthesis and modeling evaluation

  摘要：

  The design, synthesis, and capacity to inhibit HIF prolyl 4-hydroxylases (PHDs) are described for 2-[2-(3-hydroxy-pyridin-2-yl)-thiazol-4-yl]-acetamide analogs. These analogs revealed two kinds of novel scaffolds as PHD2 inhibitors. Synthetic routes were developed for the preparation of their analogs containing the new scaffolds. In addition, the structure-activity relationship (SAR) of the 2-[2-(3-hydroxy-pyridin-2yl)-thiazol-4-yl]-acetamide derivatives and their biological activities were reported. The complex structure of compound 18 with PHD2 was also obtained for the purpose of more efficient lead optimization. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.003

文献信息

• [EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET UTILISATIONS DE CES DERNIERS
  申请人：YUMANITY THERAPEUTICS

  公开号：WO2018081167A1

  公开（公告）日：2018-05-03

  The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本发明涉及对神经系统疾病治疗中有用的化合物。本发明的化合物，单独或与其他药用活性剂结合，可用于治疗或预防神经系统疾病。
• [EN] COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUVANT ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE C-KIT
  申请人：IRM LLC

  公开号：WO2013033203A1

  公开（公告）日：2013-03-07

  The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

  这项发明提供了化合物及其药物组合物，这些化合物可用作蛋白激酶抑制剂，以及使用这些化合物来治疗、改善或预防与异常或失调激酶活性相关的疾病的方法。在某些实施例中，该发明提供了使用这些化合物来治疗、改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα、PDGFRβ）激酶异常激活的疾病或紊乱的方法。
• [EN] PGDH INHIBITORS AND METHODS OF MAKING AND USING<br/>[FR] INHIBITEURS PGDH ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
  申请人：MYOFORTE THERAPEUTICS INC

  公开号：WO2021151014A1

  公开（公告）日：2021-07-29

  Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels.

  本文披露了一些可以抑制15-羟基前列腺素脱氢酶的化合物。这些化合物可以用于给那些可能从前列腺素水平调节中受益的受试者。
• [EN] INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] FORMULATIONS INHALÉES D'INHIBITEURS DE PGDH ET LEURS PROCÉDÉS D'UTILISATION
  申请人：EPIRIUM BIO INC

  公开号：WO2022082009A1

  公开（公告）日：2022-04-21

  Disclosed herein are compounds that can inhibit 15-hydroxyprostaglandin dehydrogenase. Such compounds may be administered to subjects that may benefit from modulation of prostaglandin levels. In some embodiments, the compounds disclosed herein are formulated for delivery via inhalation. In some embodiments, the compounds disclosed herein are useful for the treatment of respiratory disorders.

  本文所披露的化合物可以抑制15-羟基前列腺素脱氢酶。这样的化合物可以被用于给予需要调节前列腺素水平的受试者。在某些实施例中，本文所披露的化合物是通过吸入途径给予的。在某些实施例中，本文所披露的化合物对于治疗呼吸系统疾病是有用的。
• 20-hydroxyeicosatetraenoic acid production inhibitors
  申请人：——

  公开号：US20040121997A1

  公开（公告）日：2004-06-24

  A hydroxyformamidine compound represented by the following formula or a pharmaceutically acceptable salt thereof. 1 [wherein R 1 represents a substituted morpholino group, a substituted piperidino group, a piperazin-1-yl group, a substituted piperazin-1-yl group, a thiomorpholin-1-yl group, a perhydroazepin-1-yl group, a perhydroazocin-1-yl group, a tetrahydropyridin-1-yl group, a pyrrolin-1-yl group, etc. ; X represents a nitrogen atom or a group represented by CR 5 ; and R 2 to R 5 are the same or different and each represents a hydrogen atom, a C 1-4 alkyl group, a C 1-4 alkoxy group, a trifluoromethyl group or a halogen atom.] There is provided a drug which inhibits an enzyme producing 20-HETE participating in a contracting or dilating action for microvessels and an inducing action for cell proliferation in main organs such as kidney and cerebrovascular vessels.

  提供一种羟基甲酰胺化合物，其化学式如下，或其药学上可接受的盐。其中，R1代表取代的吗啡啶基团、取代的哌啶基团、哌嗪-1-基基团、取代的哌嗪-1-基基团、硫代吗啡啶-1-基基团、过氢化氮杂丙环-1-基基团、过氢化氮杂环己-1-基基团、四氢吡啶-1-基基团、吡咯烷-1-基基团等；X代表氮原子或CR5所代表的基团；R2到R5相同或不同，每个代表氢原子、C1-4烷基、C1-4烷氧基、三氟甲基或卤素原子。提供一种药物，其抑制产生20-HETE的酶，参与微血管的收缩或扩张作用，并诱导主要器官如肾脏和脑血管的细胞增殖作用。